TABLE 2.
Outcomes assessed or planned to be assessed during implementation of pharmacogenetic testing for antidepressants
| Outcomes |
All (n = 17) N (%) |
Stage of implementation | |
|---|---|---|---|
|
Implemented (n = 13) N (%) |
Planning (n = 4) N (%) |
||
| Implementation outcomes | |||
| Acceptability | 14 (82) | 11 (85) | 3 (75) |
| Adoption | 13 (76) | 10 (77) | 3 (75) |
| Costs | 13 (76) | 10 (77) | 3 (75) |
| Feasibility | 13 (76) | 11 (85) | 2 (50) |
| Penetration | 12 (71) | 11 (95) | 1 (25) |
| Appropriateness | 10 (59) | 8 (62) | 2 (50) |
| Fidelity | 10 (59) | 8 (62) | 2 (50) |
| Sustainability | 9 (53) | 7 (54) | 2 (50) |
| Service outcomes | |||
| Effectiveness | 14 (82) | 13 (100) | 1 (25) |
| Safety | 13 (76) | 12 (92) | 1 (25) |
| Timeliness | 12 (71) | 10 (77) | 2 (50) |
| Patient‐centeredness | 10 (59) | 9 (69) | 1 (25) |
| Efficiency | 6 (35) | 4 (31) | 2 (50) |
| Equity | 6 (35) | 6 (46) | 0 (0) |
| Patient outcomes | |||
| Symptomatology | 12 (71) | 11 (85) | 1 (25) |
| Satisfaction | 9 (53) | 8 (62) | 1 (25) |
| Function (QOL) | 6 (35) | 5 (38) | 1 (25) |
| Impact on health and social policy | 3 (18) | 3 (23) | 0 (0) |
Outcomes from Proctor et al. 20
Abbreviation: QOL, quality of life.